

Active substances set

Search phrase: zanubrutinib

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

non-Hodgkin lymphoma

Zanubrutinib	Zanubrutinib in combination with obinutuzumab is indicated for the treatment of adult patients with refractory or relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.	NO REIMBURSEMENT ESMO

Multiple myeloma and plasma cell neoplasms

Zanubrutinib	Zanubrutinib as monotherapy is indicated for the treatment of adult patients with Waldenström's macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.	FULL REIMBURSEMENT ESMO

Chronic lymphoid leukemia

Zanubrutinib	Zanubrutinib as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL).	FULL REIMBURSEMENT ESMO